Protein disulfide-isomerase A3 (PDIA3) (PDIA3)

Protein disulfide-isomerase A3 (PDIA3), widely known as ERp57, is a member of the protein disulfide isomerase (PDI) family that functions as a thiol-disulfide oxidoreductase and a molecular chaperone [1]. While primarily localized within the endoplasmic reticulum to assist in the folding of glycosylated proteins, ERp57 is rapidly translocated to the platelet surface upon activation by agonists such as thrombin or collagen [2, 3]. On the platelet surface, it plays a pivotal role in thrombus formation by regulating the activation of integrins, specifically integrin alpha-IIb/beta-3 (GPIIb/IIIa), through the isomerization of disulfide bonds [3, 4]. This makes ERp57 a significant therapeutic target for antithrombotic drugs, as its inhibition has been shown to reduce platelet aggregation and fibrin deposition in vivo [2, 4]. Small molecules like rutin and punicalagin have been identified as inhibitors of ERp57 activity, demonstrating potential in preventing cardiovascular events like stroke and myocardial infarction [4]. However, therapeutic development must balance the prevention of pathological thrombosis with the maintenance of normal hemostasis to avoid excessive bleeding risks [3].

Other names

ERp57ERp60GRP5858 kDa glucose-regulated proteinPlatelet ERp57

Inhibition of the thiol-disulfide oxidoreductase activity of ERp57, which prevents the reduction and isomerization of disulfide bonds on platelet surface receptors like integrin alpha-IIb/beta-3, thereby inhibiting platelet aggregation and thrombus formation [2, 3].